Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Mixed results for Lyme disease vaccine hit Valneva shares

An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday, ...

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed ‌more than 70% efficacy in a ...

Lyme disease vaccine shows 70 percent efficacy, Pfizer says

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the ...

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 ...

Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...
pharmaphorum

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Pfizer and Valneva have said they will still file for approval of their vaccine candidate for Lyme disease – even though ...
The Pharma Letter

Strong efficacy in Phase III for Pfizer/Valneva’s Lyme disease vaccine

US pharma giant Pfizer and French vaccine maker Valneva today announced top-line results from the Phase III VALOR "Vaccine ...
STAT

Pfizer’s Lyme vaccine results set up tricky regulatory path

New results on Pfizer's Lyme disease vaccine, how the Middle East conflict could strain drug supply chains, and more biotech ...

Pfizer says long-awaited Lyme vaccine was effective in study

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though ...
FINCHANNEL

Pfizer, Valneva Report Strong Phase 3 Results for Lyme Disease Vaccine Candidate

Valneva SE announced encouraging Phase 3 trial results for their investigational Lyme disease vaccine candidate, marking a potential breakthrough against one of the most common vector-borne illnesses ...